Skip to main content

Advertisement

SpringerLink
Log in

Hypertensive Disorders of Pregnancy and Heart Failure Risk

  • Hypertension and the Heart (B Upadhya, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To review the data on hypertensive disorders of pregnancy (HDP) and heart failure (HF) risk.

Recent Findings

Hypertensive disorders are the most common medical condition affecting women during pregnancy and are associated with future HF risk, including peripartum cardiomyopathy, pregnancy-associated HF with preserved ejection fraction, and new-onset HF later in life. HF related to HDP can occur during pregnancy and persist long term, as can be the case with peri-partum cardiomyopathy, or can develop years after delivery through mechanisms that have yet to be clearly defined. Unfortunately, the optimal ways to prevent HDP and its associated HF risks are unclear.

Summary

Guidelines outlining appropriate risk stratification, coordination of postpartum medical care, and prevention of future cardiovascular disease among with HDP are urgently needed in order to decrease the risk of HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC State-of-the-Art Review. J Am College Cardiol. 2020;75:2602–2618. Comprehensive review of primary prevention in women, and sex-specific risk factors to incorporate into risk management.

  2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–72.

    Article  PubMed  Google Scholar 

  3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.

    PubMed  Google Scholar 

  4. • Honigberg MC, Riise HKR, Daltveit AK, Tell GS, Sulo G, Igland J, et al. Heart failure in women with hypertensive disorders of pregnancy: insights from the cardiovascular disease in Norway project. Hypertension. 2020;76:1506–1513. Demonstration of strong relationship between recurrent preeclampsia and heart failure.

  5. Haug EB, Horn J, Markovitz AR, Fraser A, Klykken B, Dalen H, et al. Association of conventional cardiovascular risk factors with cardiovascular disease after hypertensive disorders of pregnancy: analysis of the Nord-Trøndelag health study. JAMA Cardiol. 2019;4:628–35.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Arnott C, Patel S, Hyett J, Jennings G, Woodward M, Celermajer DS, et al. Women and cardiovascular disease: pregnancy, the forgotten risk factor. Heart Lung Circ. 2020;29:662–7.

    Article  PubMed  Google Scholar 

  7. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:391–403.

    Article  PubMed  Google Scholar 

  8. Hypertension in pregnancy. executive summary. Obstet Gynecol. 2013;122:1122–31.

    Article  Google Scholar 

  9. •• ACOG Practice Bulletin No. 222: Gestational hypertension and preeclampsia. Obstetrics and gynecology. 2020;135:e237. Definition and current statistics on HDP.

  10. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. The lancet. 2006;367:1066–74.

    Article  Google Scholar 

  11. Singh GK, Siahpush M, Liu L, Allender M. Racial/ethnic, nativity, and sociodemographic disparities in maternal hypertension in the United States, 2014–2015. Int J Hypertens. 2018;2018:7897189.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009;113:1299–306.

    Article  PubMed  Google Scholar 

  13. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011–2013. Obstet Gynecol. 2017;130:366–73.

    Article  PubMed  PubMed Central  Google Scholar 

  14. • Hauspurg A, Ying W, Hubel CA, Michos ED and Ouyang P. Adverse pregnancy outcomes and future maternal cardiovascular disease. Clin Cardiol. 2018;41:239–246. Important review of associations between HDP and future CVD.

  15. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton Cman A, et al. Preeclamps, Zaia and future cardiovascular health: a systematic review and meta-analysis. Circulation: Cardiovas Qual Outcomes. 2017;10:e003497.

  16. Stuart JJ, Tanz LJ, Missmer SA, Rimm EB, Spiegelman D, James-Todd TM, et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: an observational cohort study. Ann Intern Med. 2018;169:224–32.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Briller JE, Mogos MF, Muchira JM, Piano MR. Pregnancy associated heart failure with preserved ejection fraction: risk factors and maternal morbidity. J Card Fail. 2021;27:143–52.

    Article  PubMed  Google Scholar 

  18. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:1715–23.

    Article  PubMed  PubMed Central  Google Scholar 

  19. •• Brown HL, Warner JJ, Gianos E, Gulati M, Hill AJ, Hollier LM, et al. The American College of O and Gynecologists. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the american heart association and the American College of Obstetricians and Gynecologists. Circulation. 2018;137:e843-e852. Call-to-action for cardiologists, primary care clinicians, and obstetricians to collaborate in order to minimize future CVD risk in women.

  20. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–31.

    Google Scholar 

  21. Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis. 2007;17:228–33.

    PubMed  Google Scholar 

  22. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80:1602–6.

    Article  PubMed  Google Scholar 

  23. Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc. 2014;3:e001056.

  24. Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol. 2011;118:583–91.

    Article  PubMed  Google Scholar 

  25. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100:302–4.

    Article  PubMed  Google Scholar 

  26. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL, et al. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol. 2010;55:654–9.

    Article  PubMed  Google Scholar 

  27. Harper MA, Meyer RE, Berg CJ. Peripartum cardiomyopathy: population-based birth prevalence and 7-year mortality. Obstet Gynecol. 2012;120:1013–9.

    Article  PubMed  Google Scholar 

  28. Kao DP, Hsich E, Lindenfeld J. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart Fail. 2013;1:409–16.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, et al. Hypertensive disorders of pregnancy and peripartum cardiomyopathy: a nationwide cohort study. PLoS One. 2019;14:e0211857.

  30. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Damp J, Givertz MM, Semigran M, Alharethi R, Ewald G, Felker GM, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. JACC Heart Fail. 2016;4:380–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66:905–14.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 2009;201(171):e1-5.

    Google Scholar 

  34. Lindley KJ, Conner SN, Cahill AG, Novak E and Mann DL. Impact of preeclampsia on clinical and functional outcomes in women with peripartum cardiomyopathy. Circ Heart Fail. 2017;10.

  35. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152:509–13.

    Article  PubMed  Google Scholar 

  36. Goland S, Bitar F, Modi K, Safirstein J, Ro A, Mirocha J, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail. 2011;17:426–30.

    Article  PubMed  Google Scholar 

  37. Duran N, Günes H, Duran I, Biteker M, Ozkan M. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet. 2008;101:137–40.

    Article  PubMed  Google Scholar 

  38. Blauwet LA, Delgado-Montero A, Ryo K, Marek JJ, Alharethi R, Mather PJ, et al. 3rd. Right ventricular function in peripartum cardiomyopathy at presentation is associated with subsequent left ventricular recovery and clinical outcomes. Circ Heart Fail. 2016;9.

  39. Davis EM, Ewald G, Givertz MM, Rajagopalan N, Cooper LT Jr, Briller J, et al. Maternal obesity affects cardiac remodeling and recovery in women with peripartum cardiomyopathy. Am J Perinatol. 2019;36:476–83.

    Article  PubMed  Google Scholar 

  40. Goland S, Modi K, Hatamizadeh P, Elkayam U. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J Card Fail. 2013;19:214–8.

    Article  PubMed  Google Scholar 

  41. Thilaganathan B, Kalafat E. Cardiovascular system in preeclampsia and beyond. Hypertension. 2019;73:522–31.

    Article  CAS  PubMed  Google Scholar 

  42. Melchiorre K, Sharma R, Thilaganathan B. Cardiovascular implications in preeclampsia: an overview. Circulation. 2014;130:703–14.

    Article  PubMed  Google Scholar 

  43. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ (Clinical research ed). 2016;353:i1753.

  44. Ramsay JE, Stewart F, Greer IA, Sattar N. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG. 2003;110:1029–31.

    Article  PubMed  Google Scholar 

  45. Männistö T, Mendola P, Vääräsmäki M, Järvelin MR, Hartikainen AL, Pouta A, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127:681–90.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166–71.

    Article  CAS  PubMed  Google Scholar 

  47. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404–23.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Wu R, Wang T, Gu R, Xing D, Ye C, Chen Y, et al. Hypertensive disorders of pregnancy and risk of cardiovascular disease-related morbidity and mortality: a systematic review and meta-analysis. Cardiology. 2020;145:633–47.

    Article  PubMed  Google Scholar 

  49. Williams D. Pregnancy: a stress test for life. Curr Opin Obstet Gynecol. 2003;15:465–71.

    Article  PubMed  Google Scholar 

  50. Rich-Edwards JW, McElrath TF, Karumanchi SA, Seely EW. Breathing life into the lifecourse approach: pregnancy history and cardiovascular disease in women. Hypertension. 2010;56:331–4.

    Article  CAS  PubMed  Google Scholar 

  51. Osol G, Bernstein I. Preeclampsia and maternal cardiovascular disease: consequence or predisposition? J Vasc Res. 2014;51:290–304.

    Article  CAS  PubMed  Google Scholar 

  52. Thayaparan AS, Said JM, Lowe SA, McLean A, Yang Y. Pre-eclampsia and long-term cardiac dysfunction: a review of asymptomatic cardiac changes existing well beyond the post-partum period. Australas J Ultrasound Med. 2019;22:234–44.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Timokhina E, Kuzmina T, Strizhakov A, Pitskhelauri E, Ignatko I, Belousova V. Maternal cardiac function after normal delivery, preeclampsia, and eclampsia: a prospective study. J Pregnancy. 2019;2019:9795765.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ghossein-Doha C, van Neer J, Wissink B, Breetveld NM, de Windt LJ, van Dijk AP, et al. Pre-eclampsia: an important risk factor for asymptomatic heart failure. Ultrasound Obstet Gynecol. 2017;49:143–9.

    Article  CAS  PubMed  Google Scholar 

  55. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension. 2007;49:612–7.

    Article  CAS  PubMed  Google Scholar 

  56. Hobson SR, Lim R, Mockler JC, Gurusinghe S, Wallace EM. Role of activin A in the pathogenesis of endothelial cell dysfunction in preeclampsia. Methods Mol Biol. 2018;1710:39–52.

    Article  CAS  PubMed  Google Scholar 

  57. Roh JD, Hobson R, Chaudhari V, Quintero P, Yeri A, Benson M, et al. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. 2019;11.

  58. Shahul S, Ramadan H, Nizamuddin J, Mueller A, Patel V, Dreixler J, et al. Activin A and late postpartum cardiac dysfunction among women with hypertensive disorders of pregnancy. Hypertension. 2018;72:188–93.

    Article  CAS  PubMed  Google Scholar 

  59. deMartelly VA, Dreixler J, Tung A, Mueller A, Heimberger S, Fazal AA, et al. Long-term postpartum cardiac function and its association with preeclampsia. J Am Heart Assoc. 2021;10:e018526.

  60. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28:1–19.

    Article  PubMed  Google Scholar 

  61. Wu P, Kwok CS, Haththotuwa R, Kotronias RA, Babu A, Fryer AA, et al. Pre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis. Diabetologia. 2016;59:2518–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. •• Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, et al. Long-term cardiovascular risk in women with hypertension during pregnancy. J Am Coll Cardiol. 2019;74:2743–2754. Demonstration of the association between HDP and future CVD (including HF, CAD, aortic stenosis, and mitral regurgitation) using a large cohort from the UK Biobank.

  63. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O, et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll Cardiol. 2020;75:2323–34.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension. 2011;57:85–93.

    Article  CAS  PubMed  Google Scholar 

  65. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: US preventive services task force recommendation statement. JAMA. 2021;326:1186–91.

    Article  PubMed  Google Scholar 

  66. Rosenbloom JI, Lewkowitz AK, Lindley KJ, Nelson DM, Macones GA, Cahill AG, et al. Expectant management of hypertensive disorders of pregnancy and future cardiovascular morbidity. Obstet Gynecol. 2020;135:27–35.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Rosenbloom JI, Stwalley D, Lindley KJ, Michael Nelson D, Olsen MA, Stout MJ. Latency of preterm hypertensive disorders of pregnancy and subsequent cardiovascular complications. Pregnancy hypertens. 2020;21:139–44.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Swan HD, Borshoff DC. Informed consent–recall of risk information following epidural analgesia in labour. Anaesth intensive care. 1994;22:139–41.

    Article  CAS  PubMed  Google Scholar 

  69. Young B, Hacker MR, Rana S. Physicians’ knowledge of future vascular disease in women with preeclampsia. Hypertens pregnancy. 2012;31:50–8.

    Article  PubMed  Google Scholar 

  70. Spaan J, Peeters L, Spaanderman M, Brown M. Cardiovascular risk management after a hypertensive disorder of pregnancy. Hypertension. 2012;60:1368–73.

    Article  CAS  PubMed  Google Scholar 

  71. Brindis CD, Freund KM. The ramifications of recent health policy actions for cardiovascular care of women: progress, threats, and opportunities. Clin Cardiol. 2018;41:173–8.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Smith GN, Pudwell J, Saade GR. Impact of the New American Hypertension Guidelines on the prevalence of postpartum hypertension. Am J Perinatol. 2019;36:440–2.

    Article  PubMed  Google Scholar 

  73. Benschop L, Duvekot JJ, Versmissen J, van Broekhoven V, Steegers EAP and Roeters van Lennep JE. Blood pressure profile 1 year after severe preeclampsia. Hypertension. 2018;71:491–498.

  74. Levine LD, Nkonde-Price C, Limaye M, Srinivas SK. Factors associated with postpartum follow-up and persistent hypertension among women with severe preeclampsia. J Perinatol. 2016;36:1079–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Hauspurg A, Countouris ME, Jeyabalan A, Hubel CA, Roberts JM, Schwarz EB, et al. Risk of hypertension and abnormal biomarkers in the first year postpartum associated with hypertensive disorders of pregnancy among overweight and obese women. Pregnancy Hypertens. 2019;15:1–6.

    Article  PubMed  Google Scholar 

  76. Callaway LK, David McIntyre H, Williams GM, Najman JM, Lawlor DA, Mamun A. Diagnosis and treatment of hypertension 21 years after a hypertensive disorder of pregnancy. Aust N Z J Obstet Gynaecol. 2011;51:437–40.

    Article  PubMed  Google Scholar 

Download references

Funding

This work was not funded by any sponsor. SAG is supported by The Thomas Anstrom Fellowship in Adult Congenital Heart Disease Fund. NJP reports research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eggland’s Best, Eli Lilly, Novartis, Novo Nordisk, Regeneron, Sanofi, and Verily Life Sciences; consultation/advisory panels for Boehringer Ingelheim, Eli Lilly, AstraZeneca, and Novo Nordisk; executive committee member for trials sponsored by Novo Nordisk and by Amgen.

Author information

Authors and Affiliations

  1. Division of Cardiology, Duke University Medical Center, 2301 Erwin Rd, P.O. Box 3845, Durham, NC, 27710, USA

    Sarah A. Goldstein & Neha J. Pagidipati

  2. Duke Clinical Research Institute, Durham, NC, USA

    Neha J. Pagidipati

Authors
  1. Sarah A. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neha J. Pagidipati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Sarah A. Goldstein or Neha J. Pagidipati.

Ethics declarations

Conflict of Interest

Sara A. Goldstein declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Hypertension and the Heart

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldstein, S.A., Pagidipati, N.J. Hypertensive Disorders of Pregnancy and Heart Failure Risk. Curr Hypertens Rep 24, 205–213 (2022). https://doi.org/10.1007/s11906-022-01189-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-022-01189-2

Keywords

Search

Navigation